R
Roderich E. Schwarz
Researcher at Indiana University
Publications - 213
Citations - 6320
Roderich E. Schwarz is an academic researcher from Indiana University. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 41, co-authored 205 publications receiving 5824 citations. Previous affiliations of Roderich E. Schwarz include University of Medicine and Dentistry of New Jersey & Indiana University Health.
Papers
More filters
Journal ArticleDOI
Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database
TL;DR: Although the impact of stage migration versus improved regional disease control cannot be separated on basis of the available information, the data provide support in favor of extended lymphadenectomy during potentially curative gastrectomy for gastric cancer.
Journal ArticleDOI
Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage
TL;DR: Even in transmural or serosa-positive gastric cancer with advanced nodal involvement, more extensive LN dissection and analysis influences survival, and stage-based survival prediction depends on total LN number and number of negative LNs.
Journal ArticleDOI
Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database
TL;DR: Stage-based survival prediction of pancreatic cancer is strongly influenced by total LN counts and numbers of negative LN obtained, and an attempt to resect and examine at least 15 LNs to yield preferably between 10 and 15 negative LNs seems sensible for curative-intent pancreatectomy.
Journal ArticleDOI
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
TL;DR: It is concluded that CK17 is a useful marker in separating pancreatobiliary adenocarcinomas from extra-pancreatobiliary nonmucinousAdenocARCinomas, including adenOCarc inomas from the colon, breast, gynecologic organs, stomach, lung, prostate, thyroid, kidney, and adrenal gland, and malignant mesothelioma.
Journal ArticleDOI
Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases
William G. Rule,Robert Timmerman,Liyue Tong,Ramzi Abdulrahman,Jeffrey J Meyer,T. Boike,Roderich E. Schwarz,Paul T. Weatherall,L. Chinsoo Cho +8 more
TL;DR: A dose of 60 Gy in 5 fractions can be safely delivered to selected patients with hepatic metastases as long as the critical liver volume is respected and an excellent level of LC is reached.